Objective: SGA is one of major causes of short stature in children. It has been known that the effectiveness of growth hormone(GH) treatment for short SGA children depends on the GH dose, the age of the child and family-corrected individual height (Albananase A et al, Horm Res, 1997). This study was conducted to see the growth response to treatment by bone-age(BA) in short SGA children. Method: Study patients consisted of 29 shot stature of SGA children. Their age at diagnosis(yrs) was 7.2 ± 1.9. Male to female ratio was 10 : 17. Their medical records were reviewed retrospectively. Results: Eighteen patients(67%) showed ＞2yrs BA delay when compared with chronological age(delayed BA group). Nine patients(33%) showed 2yr BA delayed(control group). In delayed BA group, initial height SDS was significantly increased at 6 months after treatment, when compared with ‘control group’, -2.45±0.34 to -1.87±0.82 in ‘delayed BA group’(p=0.012) vs -2.68±0.58 to -2.50±0.61 in ‘control group’(p=0.538). At 12 months after treatment, ‘delayed BA group’ showed significant height increased, -2.45±0.34 to -1.63±0.65 in ‘delayed BA group’(p=0.001) vs -2.68±0.58 to -2.27 ±0.70 in ‘control group’(p=0.483). Age at diagnosis, initial serum IGF-1 level and BMI were not significantly different between two groups. Conclusion: Delayed BA(＞2yrs) could be one of factors related to the magnitude of the growth response to treatment in short stature SGA children. Further large-scaled long term study is necessary.